Eli Lilly and Company (NYSE: LLY) has announced the successful completion of its $1.4 billion acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a notable radiopharmaceutical company. This acquisition, worth $12.5 per share in cash, marks a significant step in Eli Lilly’s expansion in cancer treatment solutions. Advancing Cancer Treatments The acquisition brings together POINT’s […]
Eli Lilly and Company (NYSE: LLY) is set to acquire POINT Biopharma Global, Inc. (NASDAQ: PNT), a leading radiopharmaceutical firm, marking a significant leap in cancer treatment innovations. This acquisition integrates POINT Biopharma Global’s radioligand therapies, which precisely target cancer cells, promising enhanced tumor efficacy and minimized impact on healthy tissues. POINT Biopharma Global’s cutting-edge […]
Loxo@Lilly, the oncology division of Eli Lilly and Company (Lilly), has secured the accelerated approval of the US Food and Drug Administration (FDA) for Jaypirca (pirtobrutinib) for the treatment of mantle cell lymphoma (MCL). To be available in 100mg and 50mg tablets, Jaypirca is specifically indicated for the treatment of adult patients having relapsed or […]